A cost analysis of bone morphogenetic protein versus autogenous iliac crest bone graft in single-level anterior lumbar fusion.
An economic model was developed to compare costs of stand-alone anterior lumbar interbody fusion with recombinant human bone morphogenetic protein 2 on an absorbable collagen sponge versus autogenous iliac crest bone graft in a tapered cylindrical cage or a threaded cortical bone dowel. The economic model was developed from clinical trial data, peer-reviewed literature, and clinical expert opinion. The upfront price of bone morphogenetic protein (3380 dollars) is likely to be offset to a significant extent by reductions in the use of other medical resources, particularly if costs incurred during the 2 year period following the index hospitalization are taken into account.
Orthopedic Surgery Service, Walter Reed Army Medical Center, Washington, DC 20307-5001, USA.
David W
DW
Polly
Stacey J
SJ
Ackerman
Christopher I
CI
Shaffrey
James W
JW
Ogilvie
Jeffrey C
JC
Wang
Susan W
SW
Stralka
Michael S
MS
Mafilios
Stephen E
SE
Heim
Harvinder S
HS
Sandhu
D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000191:economics*; D018786:Bone Substitutes / Q000191:economics*; D016025:Bone Transplantation / Q000191:economics*; D003365:Costs and Cost Analysis; D017048:Health Care Costs; D017721:Hospital Costs; D006801:Humans; D007085:Ilium / Q000637:transplantation; D008159:Lumbar Vertebrae; D018803:Models, Economic; D011994:Recombinant Proteins; D013123:Spinal Fusion / Q000191:economics*; D016212:Transforming Growth Factor beta; D014481:United States
C525718:BMP2 protein, human; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D018786:Bone Substitutes; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; C499469:recombinant human bone morphogenetic protein-2